Evaluating New PTSD Tests CAPS-5 and PSSI-5 in Adults Who Are Active Duty Military or Veterans

What this Trial Is About

Researchers are evaluating the reliability and validity of two new PTSD assessment tools, the Clinician Administered PTSD Scale for DSM-5 CAPS-5 and the PTSD Symptom Scale Interview for DSM-5 PSSI-5, in active duty military personnel and veterans aged 18 or older who have experienced traumatic events. The study also compares these new tools to the previous standard, the CAPS-IV, while exploring biomarkers related to PTSD such as biofluid markers, cognitive and physiological indicators, and brain activity measured by EEG. This research aims to improve diagnosis and treatment approaches for PTSD in this population. Participants are randomly assigned to one of four cohorts. Cohorts 1 and 2 focus on test-retest reliability of CAPS-5 and PSSI-5 respectively, with participants completing between two and seven visits some continue with additional visits including cognitive, behavioral assessments, and biofluid sample collection. Cohort 3 compares CAPS-5 and PSSI-5 through three visits, while Cohort 4 compares CAPS-IV and CAPS-5 over three visits, including similar assessments and sample collections. The study uses multiple visits and assessments to thoroughly evaluate the consistency and validity of these diagnostic tools. During the study, participants undergo multiple office visits where they complete PTSD assessments, cognitive and behavioral tests, and provide biofluid samples. Researchers measure test-retest reliability over intervals of about one week and six weeks, and correlations among the different PTSD assessments. Safety and mental health status are monitored throughout. The total involvement may range from two to seven visits depending on cohort and group assignment. The study collects detailed data to better understand PTSD diagnosis and related biomarkers in veterans and active duty military members.

An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample